References
- Ampyra® (dalfampridine extended release tablets) [prescribing information]Ardsley, NYAcorda Therapeutics, Inc2012
- GoodmanADBrownTRCohenJAFampridine MS-F202 Study GroupDose comparison trial of sustained-release fampridine in multiple sclerosisNeurology200871151134114118672472
- GoodmanADBrownTRKruppLFampridine MS-F203 InvestigatorsSustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trialLancet2009373966573273819249634
- GoodmanADBrownTREdwardsKRMSF204 InvestigatorsA phase 3 trial of extended release oral dalfampridine in multiple sclerosisAnn Neurol201068449450220976768
- DunnJBlightADalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosisCurr Med Res Opin20112771415142321595605
- HautSRBienenEJMillerAClinical overview of the seizure risk of dalfampridineExpert Opin Drug Saf201211465165722703551
- BeverCTJrYoungDAndersonPAThe effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trialNeurology1994446105410598208399
- Van DiemenHAPolmanCHKoetsierJCVan LoenenACNautaJJBertelsmannFW4-aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safetyClin Neuropharmacol19931631952048504436
- CornblathDRBienenEJBlightARThe safety profile of dalfampridine extended release in multiple sclerosis clinical trialsClin Ther20123451056106922497693
- NicolettiASofiaVBiondiREpilepsy and multiple sclerosis in Sicily: a population-based studyEpilepsia200344111445144814636354
- PoserCMBrinarVVEpilepsy and multiple sclerosisEpilepsy Behav20034161212609222
- ErikssonMBen-MenachemEAndersenOEpileptic seizures, cranial neuralgias and paroxysmal symptoms in remitting and progressive multiple sclerosisMult Scler20028649549912474990
- Acorda Therapeutics Inc.Ampyra (dalfampridine) Extended Release Tablets. Risk Evaluation and Mitigation StrategyArdsley, NYAcorda Therapeutics2010 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000REMS.pdf. Accessed November 20, 2012.
- US Food and Drug Administration FDA Adverse Event Repor ting System (FAERS) (formerly AERS). Updated September 10, 2012. Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/. Accessed December 5, 2012.
- KochMUyttenboogaartMPolmanSDe KeyserJSeizures in multiple sclerosisEpilepsia200849694895318336559
- KelleyBJRodriguezMSeizures in patients with multiple sclerosis: epidemiology, pathophysiology and managementCNS Drugs2009231080581519739692
- JaraMSidovarMHenneyHR3rdPrescriber utilization study of dalfampridine extended release tablets [abstract]Int J MS Care201214Suppl 234
- SiegertRJAbernethyDADepression in multiple sclerosis: a reviewJ Neurol Neurosurg Psychiatry200576446947515774430